If you’re considering treatment for opioid use disorder (OUD), your doctor may recommend Sublocade. It’s prescribed as part of a complete treatment program to manage opioid addiction in adults with ...

Sublocade (buprenorphine) is a brand-name prescription medication. It’s approved by the Food and Drug Administration (FDA) to treat moderate to severe opioid use disorder in people who received ...

Sublocade (buprenorphine) is a prescription drug that’s used to treat opioid use disorder. Sublocade can cause side effects that range from mild to serious. Examples include injection site reaction, ...

Patients not already receiving buprenorphine can receive the first injection of Sublocade following a single dose of transmucosal buprenorphine and a 1 hour observation period to confirm tolerability.

Sublocade (buprenorphine) is a brand-name extended-release injection that’s prescribed for opioid use disorder. Sublocade has interactions with alcohol, some other drugs, and certain supplements.

Rapid initiation Protocol: Healthcare providers can now initiate treatment with SUBLOCADE after a single dose of transmucosal buprenorphine and a one-hour observation period to confirm ...

The trial also demonstrated that administering the second SUBLOCADE injection just one week after the first was well tolerated in both treatment arms as the safety profile up to injection two was ...

SLOUGH, England and RICHMOND, Va., April 5, 2019 /PRNewswire/ -- Indivior PLC (LON: INDV) today announced data from two studies evaluating efficacy and long-term safety of once-monthly SUBLOCADE™ ...

RICHMOND, Va., Oct. 15, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) this week published compelling results from a multicenter, open-label clinical trial published in JAMA Network Open. Two ...